KR20160082863A - Composition for improving intestinal immune system comprising plant originated lactic acid bacteria, Lactobacillus plantarum PMO08 as an active ingredient - Google Patents

Abstract

Lactobacillus plantarum pmo08, which is a vegetable lactic acid bacterium, or a mixture of Lactobacillus plantarum pmo08, Lactobacillus sakei, and Pediococcus pentosaceus of the present invention adjusts the secretion of immunoglobulin A, thereby being effective in improving an intestinal immune system. Thus, microorganisms of the present invention can be used to enhance the intestinal immune system. To achieve the purpose of the present invention, the present invention provides a medical composition for improving an intestinal immune system, comprising the vegetable lactic acid bacterium mixture of Lactobacillus plantarum pmo08, Lactobacillus sakei, and Pediococcus pentosaceus.

Description

[0001] The present invention relates to a composition for improving intestinal immunity comprising lactic acid bacteria Lactobacillus plantarum pimio 08 as an active ingredient,

The present invention relates to a novel use of plant lactobacillus Lactobacillus plantarum pimio 08, and more particularly to a novel use of plant lactobacillus plantarum pumio 08 or lactobacillus plantarum pumio 08, The present invention relates to a composition for improving intestinal immunity, which comprises a mixture of a plant oil Lactobacillus bacterium and a Pediococcus pentosaceus plant as an active ingredient.

Lactic acid bacteria, which are abundant in fermented foods, play a role in decomposing fibrous and complex proteins into important nutritional components in a symbiotic relationship with the digestive system of the human body. Thus, the intestinal microbial environment of the host is improved in the gastrointestinal tract of animals including humans Living microorganisms that have a beneficial effect on the health of the host are collectively referred to as probiotics.

Lactic acid bacteria are lactic acid bacteria that produce carbohydrates and make lactic acid by using them. They are tuberous anaerobes or organisms that grow well in low oxygen. Lactic acid bacteria can be divided into five genus, Streptococcus, Lactobacillus, Leuconostoc, Bifidobacteria and Pediococcus.

The streptococcus microorganism, a streptococcus strain, is a homozygous fermenting microorganism. It is known to inhibit spoilage bacteria and pathogens by fermenting milk to produce lactic acid. Lactobacillus microorganisms are homozygous or heterozygous fermenting lactic acid bacterium, which are common bacteria in the fermentation process of dairy products and vegetables. The microorganisms of the genus Lucococcus are heterozygous and mainly involved in the fermentation of vegetables. Bifidobacterial microorganisms are organisms that do not grow in the presence of oxygen, and fermentation of sugars produces L (+) -like lactic acid, which can be metabolized to infants. Finally, the microorganism of Pediococcus is a homozygous fermenting microorganism in the form of sycamore, which is present in kimchi or pickled food and is involved in the fermentation of meat such as sausage.

Among them, microorganisms of the genus Lactobacillus are lactic acid bacterium that is homozygous or heterozygous fermenting, and are commonly found in the fermentation process of intestines, dairy products and vegetables of animals including humans. Lactobacillus microorganisms maintain intestinal pH acidic and inhibit the growth of harmful microorganisms such as E. coli and Clostridium, and improve diarrhea and constipation, as well as vitamin synthesis, anti-cancer effects, serum cholesterol lowering And so on. Acidophilin produced by lactic acid bacterium is known to inhibit the growth of Alzheimer, Salmonella, Staphylococcus, and Escherichia coli. It inhibits the growth of diarrheal pathogens and normalizes intestinal microflora to stop diarrhea.

Recently, the function of Lactobacillus plantarum isolated from plants such as vegetables and fruits, or foods fermented with fruit and vegetables such as kimchi has been revealed and emerged as a new functional material. Lactobacillus Flora Room Acid resistance, biliary and antibiotic resistance effects of Jay 124 (Korean Patent Application No. 2002-0049220), Lactobacillus Flora Room Jay 9 (Korean Patent Application No. 2003-0067073), Listeria Monocytogenes and Enterococcus Anticancer Activity against Lactobacillus , Lactobacillus Flora Room The antioxidant and anti-inflammatory efficacy of Hewlett-Packard 7711 (Korean Patent Application No. 2009-0058180) has been disclosed. Most recently, Lactobacillus , which has anticancer or antimicrobial activity, Planta room piem O 0 8 has a bar (Republic of Korea Patent Application No. 2009-0130699 call) is started.

However, the above results confirmed the physiological activity against the sole use of lactic acid bacteria, and there was a limit in considering the method for enhancing the effect of lactic acid bacteria.

Accordingly, the inventors of the present invention have been studying the function of Lactobacillus plantarum pimio 08 (KFCC-11028), which is a kind of plant lactobacillus, while Lactobacillus plantarum pimio 08 (KFCC-11028) In particular, it was found that Lactobacillus saccharum and Pediococcus pentosaceus complex isolated from kimchi exerted a superior immunity enhancing effect and completed the present invention.

It is therefore an object of the present invention to provide a novel use of a mixture of Lactobacillus plantarum pmi 08 (KFCC-11028) lactobacillus or Lactobacillus plantarum pumio lactobacillus, Lactobacillus sac and Pediococcus pentosaceus will be.

In order to achieve the object of the present invention, the present invention provides a pharmaceutical composition comprising Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacterium, Lactobacillus casei, Pediococcus pentosaceus plant lactic acid bacteria mixture as an active ingredient Or a pharmaceutically acceptable salt thereof.

In order to accomplish another object of the present invention, the present invention provides a pharmaceutical composition comprising lactobacillus plantarum pmi-08 (KFCC-11028) lactic acid bacteria and a mixture of lactobacillus saccharides and Pediococcus pentosaceus vegetable lactic acid bacteria as an active ingredient Wherein the composition of the present invention is an immunosuppressive composition.

In order to accomplish still another object of the present invention, there is provided a pharmaceutical composition for improving intestinal immunity, which comprises Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacterium as an active ingredient.

In order to accomplish still another object of the present invention, there is provided a composition for improving gastrointestinal immunity, which comprises Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacterium as an active ingredient.

Hereinafter, the present invention will be described in detail.

The present invention provides a composition for improving intestinal immunity, which comprises lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacteria, and a mixture of lactobacillus sake and pediococcus pentosaceous plant lactobacillus as an active ingredient.

In one embodiment of the present invention, the immunity enhancement by the forced swimming load was induced, and the immunity enhancement effect according to the lactic acid bacteria consumption was confirmed. As a result, it was confirmed that the lactobacillus plutarum pyrophosphate lactobacillus of the present invention had a decrease in immobility time of about 17% and a serum interferon gamma content of 17%, which is an immunological indicator, as compared with the control group. Particularly, in the mixture of Lactobacillus plantarum pmi-08 and Lactobacillus sacae and Pediococcus pentosaceus, the immobilization time was reduced by 50% or more and the serum interferon gamma content was increased by 35% (See Example <1-2>).

 In another embodiment of the present invention, immunoglobulin A (sIgA), which is the most secreted in the intestinal tract, was measured as a biomarker in order to measure the intestinal immunity due to lactic acid bacteria ingestion. As a result, it was confirmed that the mixture of lactic acid bacteria and vegetable lactic acid bacteria according to the present invention increased the immunoglobulin A secreted by the feces by 135% and 200%, respectively, and thus proved to be excellent in enhancing the immunity of the colon (see Example <2-2> ).

Accordingly, it has been confirmed in the present invention that Lactobacillus plantarum pmi 08 (KFCC-11028), which is a kind of vegetable lactic acid bacteria, has an excellent effect on the improvement of intestinal immunity, and provides a composition for improving gastrointestinal immunity, which comprises the effective ingredient. In particular, the composition of the present invention may contain Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacteria, Lactobacillus sac, and Pediococcus pentosaceus as active ingredients. The mixture of vegetable lactic acid bacteria reduced the amount of lactobacillus plantarum pimozo 08, which is a vegetable lactic acid bacterium, to a considerable extent, and a useful effect of obtaining a better effect even with a smaller number of lactic acid bacteria (about 1/3 in the experiment) . Particularly in the intestinal immunoglobulin A secretion ability, a synergistic effect superior to the exclusive consumption of lactic acid bacteria was observed.

Meanwhile, the composition of the present invention may be a pharmaceutical composition or a food composition.

The pharmaceutical composition according to the present invention can be prepared by mixing a pharmaceutically effective amount of Lactobacillus plantarum pumio lactic acid bacterium or Lactobacillus plantarum pumio lactic acid bacterium, Lactobacillus sacae and Pediococcus pentosaceus alone Or may further comprise one or more pharmaceutically acceptable carriers. The pharmaceutical compositions of the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol in which multiple doses are administered over a prolonged period of time. The pharmacologically effective amount in the above refers to an amount showing a reaction higher than that of the negative control, preferably an amount sufficient to exhibit an immunostimulating effect. The effective amount of the lactobacillus plantarum pumio lactobacillus or lactobacillus plantarum pumio lactobacillus, lactobacillus sac, and pediococcus pentosaceus mixture according to the present invention is in the range of 0.001 to 1000 mg / day / kg body weight But is not limited thereto. However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the disease and its severity, the patient's age, body weight, health condition, sex, administration route and treatment period.

The composition of the present invention can be variously formulated according to the route of administration by a method known in the art together with the pharmaceutically acceptable carrier. The term "pharmaceutically acceptable" as used herein means a non-toxic composition which is physiologically acceptable and which, when administered to humans, does not inhibit the action of the active ingredient and does not normally cause an allergic reaction such as gastrointestinal disorder, dizziness, . The composition of the present invention can be variously formulated according to the route of administration by a method known in the art together with the pharmaceutically acceptable carrier. Routes of administration include, but are not limited to, oral or parenteral administration.

When the pharmaceutical composition of the present invention is orally administered, the pharmaceutical composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a capsule, a liquid, a gel , Syrups, suspensions, wafers, and the like. Examples of suitable carriers include saccharides including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethyl-cellulose and the like, fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In addition, when parenterally administered, the pharmaceutical composition of the present invention can be formulated according to a method known in the art together with a suitable parenteral carrier.

Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., 1995, Mack Publishing Company, Easton, PA).

Furthermore, the pharmaceutical composition of the present invention can be administered in combination with a known compound having an effect of preventing and treating constipation.

In addition, the lactobacillus plantarum pumio lactobacillus or the lactobacillus plantarum pumio lactobacillus, the lactobacillus sac, and the pediococcus pentosaceus mixture according to the present invention can be used as a food composition As shown in FIG. The food composition of the present invention includes all forms of functional food, nutritional supplement, health food and food additives, lactic acid bacteria drink, fermented milk, green juice and the like. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as a health food, a mixture of Lactobacillus plantarum pumio lactobacillus or Lactobacillus plantarum pumio lactobacillus, Lactobacillus sacae and Pediococcus pentosaceus of the present invention may be used as a green juice, , Fermented milk, tea, juice and drink, and may be ingested, granulated, tableted, encapsulated and powdered. In addition, the lactobacillus plantarum pumio lactobacillus or lactobacillus plantarum pumio lactobacillus, the lactobacillus sac, and the pediococcus pentosaceus mixture of the present invention may be a known substance known to have an effect of improving the immune system or Can be prepared in the form of a composition by mixing together with the active ingredient.

Functional foods also include beverages (including alcoholic beverages), fruits and their processed foods (such as canned fruits, bottled, jam, marmalade, etc.), fish, meat and processed foods such as ham, sausage, Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), juice, various drinks, cookies, sugar, dairy products such as butter, cheese, edible vegetable oil, vegetable protein, retort food, , Lactic acid bacteria of the present invention such as Lactobacillus plantarum pneumo 08 lactobacillus or Lactobacillus plantarum pumio lactic acid bacterium of the present invention and lactobacillus sacae and Pediococcus pentosaceus mixture And the like.

The preferred content of the lactobacillus plantarum pumio lactobacillus or the lactobacillus plantarum pumio lactobacillus, the lactobacillus sac, and the pediococcus pentosaceus mixture in the food composition of the present invention is not particularly limited, Is from 0.001 to 50% by weight of the final produced food.

In order to use the Lactobacillus plantarum pumio lactobacillus or Lactobacillus plantarum pumio lactobacillus, Lactobacillus sac, and Pediococcus pentosaceus of the present invention in the form of a food additive, Can be used.

As described above, the lactobacillus plantarum pumio lactobacillus or the lactobacillus plantarum pumio lactobacillus, the lactobacillus sac, and the pediococcus pentosaceus mixture of the present invention can control the secretion of immunoglobulin A from the intestinal tract And is effective in improving the immune system. Therefore, the lactic acid bacterium of the present invention can be used for the purpose of improving intestinal immunity.

Fig. 1 shows floating time of each experiment group.
Fig. 2 shows the immunoglobulin A secretion ability of each experimental group.

Hereinafter, the present invention will be described in detail by way of examples.

However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.

< Example  1>

compulsion In swimming load  Evaluation of immunity by

<1-1> Experimental group  Setup and processing

As shown in Table 1 below, the experimental animals (ICR mice, 7 weeks old) were divided into five groups from G1 to G5 in the experimental group, and all the experimental groups were divided into two groups as Lactobacillus plantarum pumioi 08, Lactobacillus sake Alone, Pediococcus pentosaceus alone or a combination of vegetable lactic acid bacteria was administered in the same dose of each individual for 7 days in the stomach once / day.

Experimental group Experimental material Dose Number of animals G1 Control group - 8 G2 Lactobacillus Planta Room PM08 0.5 g / body weight 8 G3 Lactobacillus saccharae 0.5 g / body weight 8 G4 Pediococcus pentosaceus 0.5 g / body weight 8 G5 Vegetable lactic acid bacteria complex 0.5 g / body weight 8

Lactobacillus planta PMO08 Lactobacillus and Pediococcus pentosaceus used the raw materials produced by CELL BIOTECH and used Lactobacillus from Lactobacillus sakei. Each lactic acid bacterium was inoculated into MRS medium at a concentration of 2% by weight, and subcultured at 37 ° C for 18 hours for 2 hours. After completion of the culture, centrifugation was performed at 3,000 rpm to remove the supernatant. PBS was added thereto to adjust the concentration of the lactic acid bacteria to ^1.0 × ^{10 10} cfu / ml.

<1-2> Floating time measurement by forced swimming

In order to evaluate the immune improvement effect, the immobility time due to the forced swimming load was measured as follows. In FIG. 1, the immobility time was measured while the forced swimming was carried out for 15 minutes after the experimental diet was administered for 7 days in the example <1-1>, and the immersion time was measured by the experimental group.

Compared with G1, a group not administered with the test substance, the group to which Lactobacillus plantarum pimio 08 was administered showed a decrease in the immobilization time by 17%, and Lactobacillus plantarum pumio 08 and Lactobacillus sake and Pediococcus It was confirmed that the immobilization time can be remarkably lowered in the combined administration group of pentosashex (see Fig. 1).

<1-3> Measurement of blood interferon gamma by forced swimming

In order to evaluate the immunity improving effect, blood interferon gamma by forced swimming load was measured as follows. Interferon gamma in the blood was measured using an IFN-assay kit (mouse IFN-ELISA kit, Thermo Scientific Co., Ltd.) after completion of forced swim for 15 minutes in the above Example <1-2> 2].

Compared with G1, a group that was not administered the test substance, the group to which Lactobacillus plantarum pimono 08 was administered showed a 17% increase in the serum interferon gamma, and Lactobacillus plantarum pumio 08 and Lactobacillus sake and Pediococcus It was confirmed that the interferon gamma was significantly increased in the combination administration group of Kuspentosasus (see Table 2).

Experimental group Experimental material Interferon gamma G1 Control group 268.313.1 ^a G2 Lactobacillus Planta Room PM08 313.917.8 ^b G3 Lactobacillus saccharae 297.714.9 ^ab G4 Pediococcus pentosaceus 323.314.0 ^c G5 Vegetable lactic acid bacteria complex 362.216.4 ^d

< Example  2>

Immunoglobulin A Secretory function  evaluation

<2-1> Experimental group  Setup and processing

Experimental animals (ICR mice, 7 weeks old) were divided into five groups from S1 to S5 in the experimental group, and Lactobacillus plantarum pimio 08 (KFCC-11028) and Lactobacillus sacae Each group was administered once daily for 21 days by gavage.

Experimental group Experimental material Dose Number of animals S1 Control group - 8 S2 Lactobacillus Planta Room PM08 0.5 g / body weight 8 S3 Lactobacillus saccharae 0.5 g / body weight 8 S4 Pediococcus pentosaceus 0.5 g / body weight 8 S5 Vegetable lactic acid bacteria complex 0.5 g / body weight 8

In G5, the vegetable lactic acid bacteria complex was mixed with a mixture of Lactobacillus plantarum pimio 08 (KFCC-11028), Lactobacillus casei, and Pediococcus pentosaceus of the present invention at a ratio of 1: 1: 1.

<2-2> Measurement of immunoglobulin A content

Feces were collected from the experimental rats of Example <2-1> to measure the immunoglobulin A content, and the results of the experiment are shown in FIG. In the control group (S1), the immunoglobulin A content was 6.1 ng / mg protein. In the lactobacillus plantarum pimozo 08 administration group (S2) 8.2 ng / mg protein and the plant lactobacillus mixed administration group (S5) protein was found to be highly immunoglobulin A secreted.

Claims (4)

Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacteria, and a mixture of Lactobacillus sake and Pediococcus pentosaceus vegetable lactic acid bacteria as an active ingredient.
Lactobacillus plantarum pmi 08 (KFCC-11028) lactic acid bacteria, and a mixture of Lactobacillus sake and Pediococcus pentosaceus vegetable lactic acid bacteria as an active ingredient.

Lactobacillus plantarum pemo 08 (KFCC-11028) A pharmaceutical composition for the treatment of gastrointestinal immunity, which comprises lactic acid bacteria as an active ingredient.
Lactobacillus plantarum pemo 08 (KFCC-11028) A composition for improving gastrointestinal immunity comprising as an active ingredient a lactic acid bacterium.

Images